Page 53 - TD-4-1

Tumor Discovery WDR4 in cancer

doi: 10.1038/s41586-022-05566-4 41. Peng Y, Wang Y, Zhou C, Mei W, Zeng C. PI3K/Akt/mTOR
pathway and its role in cancer therapeutics: Are we making
30. Li R, Liu X, Deng K, Wang X. M G methylated core genes
7
(METTL1 and WDR4) and associated RNA risk signatures headway? Front Oncol. 2022;12:819128.
are associated with prognosis and immune escape in HCC. doi: 10.3389/fonc.2022.819128
BMC Med Genomics. 2023;16(1):179.
42. Meuten TK, Dean GA, Thamm DH. Review: The PI3K-
doi: 10.1186/s12920-023-01614-8 AKT-mTOR signal transduction pathway in canine cancer.
Vet Pathol. 2024;61(3):339-356.
31. Wu PR, Chiang SY, Midence R, et al. Wdr4 promotes
cerebellar development and locomotion through Arhgap17- doi: 10.1177/03009858231207021
mediated Rac1 activation. Cell Death Dis. 2023;14(1):52.
43. Zhang HP, Jiang RY, Zhu JY, et al. PI3K/AKT/mTOR
doi: 10.1038/s41419-022-05442-z signaling pathway: An important driver and therapeutic
target in triple-negative breast cancer. Breast Cancer.
32. Patel DA, Patel SS, Patel HD. Advances in synthesis and
biological evaluation of CDK2 inhibitors for cancer therapy. 2024;31(4):539-551.
Bioorg Chem. 2024;143:107045. doi: 10.1007/s12282-024-01567-5
doi: 10.1016/j.bioorg.2023.107045 44. Leiphrakpam PD, Are C. PI3K/Akt/mTOR signaling
pathway as a target for colorectal cancer treatment. Int J Mol
33. Rubin SM, Sage J, Skotheim JM. Integrating old and new
paradigms of G1/S control. Mol Cell. 2020;80(2):183-192. Sci. 2024;25(6):3178.
doi: 10.3390/ijms25063178
doi: 10.1016/j.molcel.2020.08.020
45. Hao C, Wei Y, Meng W, Zhang J, Yang X. PI3K/AKT/mTOR
34. Zhang H, Lin J, Yahaya BH. Comprehensive analysis of inhibitors for hormone receptor-positive advanced breast
co-expressed genes with TDP-43: Prognostic and therapeutic cancer. Cancer Treat Rev. 2025;132:102861.
potential in lung adenocarcinoma. J Cancer Res Clin Oncol.
2024;150(2):44. doi: 10.1016/j.ctrv.2024.102861
doi: 10.1007/s00432-023-05554-9 46. Browne IM, Okines AFC. Resistance to targeted
inhibitors of the PI3K/AKT/mTOR pathway in advanced
35. Dong S, Alahari SK. Small molecule Mcl-1 inhibitor for oestrogen-receptor-positive breast cancer. Cancers (Basel).
triple negative breast cancer therapy. Front Cell Dev Biol. 2024;16(12):2259.
2024;12:1408107.
doi: 10.3390/cancers16122259
doi: 10.3389/fcell.2024.1408107
47. Zhao P, Zhang X, Dong J, Li L, Meng X, Gao L. In vitro study
36. Nguyen D, Osterlund E, Kale J, Andrews DW. The C-terminal of the pro-apoptotic mechanism of amino acid Schiff base
sequences of Bcl-2 family proteins mediate interactions that copper complexes on anaplastic thyroid cancer. Eur J Pharm
regulate cell death. Biochem J. 2024;481(14):903-922.
Sci. 2025;206:107005.
doi: 10.1042/BCJ20210352
doi: 10.1016/j.ejps.2025.107005
37. Cauwelier C, De Ridder I, Bultynck G. Recent advances in 48. Zhang F, Wu X, Jiao T, et al. Genomic characterization
canonical versus non-canonical Ca -signaling-related anti- reveals distinct mutational landscape of acral melanoma in
2+
apoptotic Bcl-2 functions and prospects for cancer treatment. East Asian. J Genet Genomics. 2025.
Biochim Biophys Acta Mol Cell Res. 2024;1871(5):119713.
doi: 10.1016/j.jgg.2024.12.018
doi: 10.1016/j.bbamcr.2024.119713
49. You YL, Byun HJ, Chang Y, et al. Euglena gracilis-derived
38. Ummarino A, Cala N, Allavena P. Extrinsic and cell-intrinsic
stress in the immune tumor micro-environment. Int J Mol racilis, 24.12.018es particulate matter (PM )-induced
2.5
airway inflammation by modulating nuclear factor kappa B,
Sci. 2024;25(22):12403.
mitogen-activated protein kinase, and nuclear factor
doi: 10.3390/ijms252212403 erythroid 2-related factor 2 signaling pathways in A549 cells
and BALB/c mice. Int J Biol Macromol. 2025;296:139671.
39. Zhang Z, Su M, Jiang P, Wang X, Tong X, Wu G. Unlocking
apoptotic pathways: Overcoming tumor resistance in doi: 10.1016/j.ijbiomac.2025.139671
CAR-T-cell therapy. Cancer Med. 2024;13(19):e70283.
50. Wu S, Nasser BSA, Ll NG, et al. The regulatory role of
doi: 10.1002/cam4.70283 integrin in gastric cancer tumor microenvironment and
40. Wang S, Liu C, Yang C, et al. PI3K/AKT/mTOR and drug resistance. Prog Biophys Mol Biol. 2025;195:130-136.
PD1/CTLA4/CD28 pathways as key targets of cancer doi: 10.1016/j.pbiomolbio.2025.01.001
immunotherapy (review). Oncol Lett. 2024;28(6):567.
51. Lu Q, Tang X, Tao B, et al. Multifunctional hyaluronic acid
doi: 10.3892/ol.2024.14700 microneedle patch enhances diabetic wound healing in

Volume 4 Issue 1 (2025) 45 doi: 10.36922/td.5830